EPR Biotech News

May 15th 2009
Categories: Biomedical Engineering, Biopharmaceutical, Biotech, Biotech Products, Biotech Services, Biotech Solutions, Biotechnology, Genetics, Pharmaceuticals

No Comments

Michael Jenkins, Phd, Of Catalent To Present Their GPEx® Technology At The 2009 BIO Process Theatre Taking Place At This Year’s BIO International Convention

Dr. Jenkins’ talk will focus on Catalent’s proprietary GPEx technology for mammalian cell culture engineering. The 2009 BIO International Convention takes place in Atlanta, GA, May 18-21. Dr. Jenkins’ presentation is titled “Bench to the Clinic: Using GPEx® Mammalian Cell Culture Engineering to Shorten Timelines, Reduce Risk, and Prepare for Success.” ...
May 15th 2009
Categories: Biomedical Engineering, Biopharmaceutical, Biotech, Biotech Products, Biotech Services, Biotech Solutions, Biotechnology, Genetics, Pharmaceuticals

No Comments

Two Catalent Scientists, Dr. Tom Feinberg, Director Of Structural Chemistry Services, And Dr. Craig Davies-Cutting, Director Of Research And Development, Will Host A 45-Minute Interactive Workshop At RDD Europe 2009

Two Catalent scientists, Dr. Tom Feinberg, director of structural chemistry services, and Dr. Craig Davies-Cutting, director of research and development, will host a 45-minute interactive workshop at RDD Europe 2009. The conference is designed for academic, industrial and regulatory scientists involved in the development, investigation, preparation and delivery of existing ...

Pages

 

May 2009
M T W T F S S
« Apr   Jul »
 123
45678910
11121314151617
18192021222324
25262728293031

Advertisements

Categories

Recent Posts

Tags

Blogroll

Archives

Meta

January 25th 2012
Tags: Biomedical Engineering, Biopharmaceutical, Biotech, Biotech Products, Biotech Services, Biotech Solutions, Biotechnology, Genetics, Pharmaceuticals No Comments

Advinus, SignalChem Start The Multi-Year, Multi-Target Collaboration On New Anti-Cancer Drugs

Advinus Therapeutics, a research-based pharmaceutical development company promoted by the TATA Group, and SignalChem Pharmaceuticals, a British Columbia-based drug discovery company, have started working on 15 programs based on SignalChem’s proprietary Kinase platform for targeted therapies in oncology. Each program is being developed with corresponding diagnostics and tracers for patient ...
November 24th 2011
Tags: Biomedical Engineering, Biopharmaceutical, Biotech, Biotech Products, Biotech Services, Biotech Solutions, Biotechnology, Genetics, Pharmaceuticals No Comments

CYTOO Raises 10 M$ (7M€) in Series C Round

CYTOO SA, a company that specializes in cell-based assays, is pleased to announce the closing of a series C funding round of USD 10M (EUR 7M). New investors, Sham and Entrepreneurs Fund (EF), led the round. Existing investors AURIGA Partners and Jacques Lewiner, co-founder and president of the supervisory board ...

Search

The archives run deep. Feel free to search older content using topic keywords.